Menu
Not yet recruiting NCT05440123

Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation

Observational the Rate of Participation in Screening for PBC

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: screening for bronchopulmonary cancer.
Who it may be relevant to
Registry conditions: the Rate of Participation in Screening for PBC. Basic parameters: 55 years — 74 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation

Overview

The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France. In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.

Detailed description

The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France.

When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

Interventions

  • Other screening for bronchopulmonary cancer
    The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from

Primary outcome measures

  • Rate of population participation in PBC screening [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Women and men
  • Age: 55 to 74 years old
  • Smokers at more than 20 pack-years weaned for less than 15 years
  • Affiliated to a social security organization

Exclusion criteria

  • Presence of signs of PBC
  • Subjects with a personal history of PBC of less than 5 years or under treatment
  • Presence of serious comorbidities involving the vital prognosis at 6 months
  • Subjects who have already benefited from a chest CT scan less than one year old.
  • Refusal to participate in the study
  • Absence of exposure to tobacco or insufficient exposure to tobacco or withdrawal > 15 years
  • Patient on long-term oxygen therapy
  • Metal implants (thorax, spine) which can cause a deterioration in the quality of the image of the low dose scanner
  • Subject included in another study protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05440123 · LUMASCAN-2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗